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What is known 
• Esophageal squamous cell carcinoma (ESCC) is characterized by poor prognosis, 
highlighting a great need for chemo-prevention. 
• The drug metformin may have anti-cancer properties. 
• The impact of metformin use on ESCC is poorly investigated. 
What is new here 
• This nationwide population-based cohort study indicated a 32% decreased risk of ESCC in 
metformin users compared to non-users. 
• The decrease in risk remained in subgroup analyses and sensitivity analyses, indicating 





Objectives Esophageal cancer is a highly fatal malignant neoplasm, with two etiologically 
different histological types. A large prospective study is expected to elucidate the specific risk of 
the 90% subtype of esophageal cancer, esophageal squamous cell carcinoma, with metformin 
therapy. This study aims to determine the association between metformin use and incident 
esophageal squamous cell carcinoma risk. 
Methods This was a nationwide population-based prospective cohort study conducted in Sweden 
in 2005-2015. Among 8.4 million participants identified in the cohort, 411,603 (5%) were 
metformin users. The users were compared with 10 times as many frequency-matched non-users 
of metformin (n=4,116,030) by age and sex. Metformin use was treated as a time-varying variate 
and multivariable cause-specific proportional hazards model was used to calculate hazard ratios 
(HR) with 95% confidence intervals (CI) for esophageal squamous cell carcinoma, adjusted for 
age, sex, calendar year, residence area, tobacco smoking, alcohol overconsumption, and use of 
non-steroidal anti-inflammatory drugs or statins. 
Results The incidence rates of esophageal squamous cell carcinoma were 3.5 per 100,000 person-
years among the metformin users and 5.3 per 100,000 person-years in the non-users. Metformin 
users overall were at a decreased risk of esophageal squamous cell carcinoma compared with non-
users (HR 0.68, 95% CI 0.54-0.85). The decrease in risk was more pronounced in new metformin 
users (HR 0.44, 95% CI 0.28-0.64) and participants aged 60-69 years (HR 0.45, 95% CI 0.31-
0.66). 
Conclusions Metformin use decreases the risk of developing esophageal squamous cell carcinoma.  
 




Esophageal cancer is the ninth most common cancer globally, with esophageal squamous cell 
carcinoma (ESCC) as the predominant (87%) histological type (1, 2). Tobacco smoking and 
alcohol overconsumption explain more than 90% of ESCC cases in Western populations (3-5). 
The prognosis of ESCC is poor with an overall five-year survival rate below 15-20%, which 
highlights a great need for preventive measures (6). 
 
Metformin is the most commonly used anti-diabetes drug, and it has a good safety profile and few 
side effects. Interestingly, a growing number of observational studies have suggested that the use 
of metformin decreases the risk of cancer overall and a few specific cancer types in particular, i.e., 
cancer of the colon or rectum, breast, and stomach (7-11). The only recently published randomized 
clinical trial found a decreased risk of tumorous progress in colorectal adenomas or polyps among 
metformin users (12). The limited existing literature examining metformin use in relation to the 
risk of esophageal cancer has provided conflicting results (13-16). Unfortunately, none of these 
studies has separated the two main histological types of esophageal cancer, i.e., squamous cell 
carcinoma and adenocarcinoma, despite the fact that these subtypes have very different aetiology 




Study design and participants 
This was a population-based and nationwide Swedish cohort study carried out between July 1, 
2005 to December 31, 2015. The study followed a priori-established protocol. The cohort was 
established within a well-defined database, entitled the Swedish Prescribed Drugs and Health 
(SPREDH) cohort. A detailed cohort profile for SPREDH has recently been published (17). Briefly, 
SPREDH includes 8.4 million ever-users of commonly prescribed medications, included from July 
1, 2005, to December 31, 2015. The cohort participants and relevant data were identified from four 
nationwide health data registries in Sweden:  
 (1) Prescribed Drug Registry, established in 2005 (defining the start of this study) and containing 
data on all drugs prescribed and dispensed in outpatient care in the entire Swedish population;   
(2) Patient Registry, covering 100% of inpatient care since 1987 and almost all specialized 
outpatient care from both public and private caregivers since 2001 in Sweden;  
 (3) Cancer Registry, established in 1958 with 96% overall completeness for newly diagnosed 
cancers, and 98% completeness specifically for esophageal cancer with 100% histological 
confirmation;  
(4) Cause of Death Registry, established in 1952 with 100% complete coverage for the date of 
death.  
Information on drug use from the Prescribed Drug Registry included Anatomical Therapeutic 
Chemical (ATC) codes, defined daily doses (DDD), and dates of dispensing. This study was 




The study population of the present study included participants in SPREDH who were older than 
18 years and without any previous cancer diagnosis (except for non-melanoma skin cancer). 
Individuals who had used metformin before the age of 18 years were excluded. A flowchart of 
participants’ enrolment is shown in online supplementary Figure 1.  
 
The exposure was defined as having ever dispensed metformin during the study period. The 
exposed participants entered the study on the date of their first dispensation of metformin 
prescription. For each exposed participant (metformin user), ten comparison individuals in the 
cohort were randomly selected after frequency-matching by age (year of birth) and sex among 
those who had never used metformin at the time when the exposed person was identified. Thus, 
comparison individuals could become metformin users later. In addition to the total cohort 
examining all metformin users, a sub-cohort containing new (incident) metformin users and their 
matched comparison individuals was established from the original cohort. New users were defined 
as those without any metformin dispensation between July 1, 2005, and June 30, 2006 (one year’s 
observation window, the maximal validation period for one prescription in Sweden), who had their 
first prescription dispensed after this period. To reduce potential detection bias, participants who 
developed ESCC within one year after entering the sub-cohort were excluded. 
 
All participants were followed up until any of the following endpoints: diagnosis of ESCC, death, 
first metformin dispensation (non-exposed participants only) or the end of the study (December 
31, 2015), whichever occurred first. The diagnosis of ESCC was determined in the Swedish Cancer 
Registry using a combination of the disease code C15 (tumor of the esophagus) in the 10th version 
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of the International Classification of Diseases (ICD-10) and the histological codes 8050-8078 or 
8083-8084 (squamous cell carcinoma) in the third version of ICD for Oncology (ICD-O-3).  
 
Statistical analysis 
The incidence rate of ESCC and the cumulative incidence competing risk curve with K-sample 
test were calculated. We considered deaths from any cause as a competing event for incident ESCC. 
The association between metformin use and ESCC risk was assessed by time-varying analysis, 
treating metformin use as a time-dependent covariate. Multivariable cause-specific proportional 
hazards model was applied with adjustment of covariates, providing hazard ratios (HR) with 95% 
confidence intervals (CI). Time since study entry was measured as the time scale for this model. 
The proportionality assumption of the hazard was met using the scaled Schoenfeld residuals. 
Covariates included age at study entry (continuous), sex (men or women), calendar year of study 
entry (continuous), tobacco smoking (yes or no, defined by tobacco smoking-related diagnoses 
within ten years before an individual’s study entry), alcohol overconsumption (yes or no, defined 
by diagnoses related to alcohol overconsumption within ten years before entry), place of residence 
(eastern/southern Sweden or northern Sweden), use of a non-steroidal anti-inflammatory drug 
(NSAID) or aspirin (yes or no, within the year after study entry), and use of a statin (yes or no, 
within the year after study entry). Details about the ICD codes and ATC codes to identify the 
exposure, outcome, and covariates of this study are provided in online supplementary Tables 1 and 
2. Three models were used to assess the influence of covariates: (1) a crude model (model 1); (2) 
a model adjusted for age, sex, calendar year, place of residence, tobacco smoking, and alcohol 
overconsumption (model 2); and (3) a model with further adjustment for use of NSAIDs/aspirin 




Stratified analyses were conducted by age at cohort entry (18-59, 60-69, and ≥70 years), sex (men 
and women), and calendar period (2005-2009 and 2010-2015). Regarding the adjustments for 
covariates, the complete-case analysis was conducted because missing data amounted to less than 
1%.   
 
A dose-response analysis was performed among all metformin users according to the total DDD 
of metformin intake within one year after first metformin dispensation. Metformin users were 
categorised into three approximately equal-sized groups: low (<175 DDD), medium (175-300 
DDD), and high (>300 DDD) dosages. The starting time for this specific analysis was one year 
after the first metformin dispensation. P for trend was calculated by treating the metformin dosage 
as a continuous variable based on category-specific median values.  
 
The following sensitivity analyses were conducted to evaluate the robustness of the results: (1) 
Censoring participants who developed any cancer (except for non-melanoma skin cancer) before 
ESCC during the follow-up; (2) Excluding participants who were followed up for <1 year, 
regardless of exposure status and reasons for the end of follow-up. All models, except for the dose-
response analysis, have been analyzed with a clustered sandwich estimator clustered on the 
matching group of the subjects (18). 
 
To explore any protective effect of unmeasured or residual confounding over parameter 
constellations (19), a rule-out approach was applied for which prevalence of metformin use in the 
source cohort of 9% and a prevalence of a confounder of 80% was assumed. Using values found 
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in the literature (3, 20-22), odds ratios of metformin use for non-smoking and non-alcohol 
overconsumption, and the relative risk of ESCC for non-smoking and non-alcohol 
overconsumption were assumed. To evaluate adherence to metformin therapy, the percentage of 
adherent participants was calculated by dividing the number of participants who had metformin 
dispensed at least once each specific calendar year with the total number of users from the previous 
year (excluding those who met any of the study endpoints), plus new users during the current year.  
 
All analyses were performed using the statistical software package STATA MP 15.0 (StataCorp 




RESULTS            
Participants 
The total cohort included 411,603 metformin users (exposed) and 4,116,030 matched control 
participants (non-exposed). Characteristics of the participants are presented in Table 1. The mean 
age at entry was 59.0 (standard deviation [SD] 13.7) years, and 58.2% of the participants were 
men. The distribution of age, sex, residence area, tobacco smoking, and alcohol overconsumption 
was similar in users and non-users of metformin, while the use of NSAIDs and statins was more 
common in metformin users. The mean follow-up was 6.0 (SD 3.4) years in the metformin group 
and 5.8 (SD 3.5) years in the non-exposed group.  
 
The sub-cohort of only new metformin users included 264,641 participants, accounting for 64.3% 
of the metformin users in the total cohort. Characteristics of the sub-cohort of new metformin users 
are presented in online supplementary Table 3. 
 
Metformin use and esophageal squamous cell carcinoma risk 
A total of 1,352 newly diagnosed cases of ESCC occurred during follow-up. The incidence rates 
of ESCC were 3.5 per 100,000 person-years among metformin users and 5.3 per 100,000 person-
years among non-users (Table 1). Compared with non-users, metformin users had a lower 
cumulative incidence of ESCC (p<0.001; Figure 1). Metformin use was associated with a 
decreased HR of ESCC (adjusted HR 0.67, 95% CI 0.54-0.84, model 2) and the HR was similar 
after further adjustment for the use of NSAIDs/aspirin and statins (adjusted HR 0.68, 95% CI 0.54-
0.85, model 3) (Table 2). The HR was lower among new users of metformin (adjusted HR 0.46, 




Stratified analyses showed a risk reduction among metformin users in both women (adjusted HR 
0.62, 95%CI 0.39-0.97, model 3) and men (adjusted HR 0.70, 95% CI 0.54-0.90, model 3), and in 
participants aged 60-69 years (adjusted HR 0.45, 95% CI 0.31-0.66), but not in the younger or 
older age groups (Table 3). A decreased risk was found for both calendar periods (Table 3). 
 
The dose-response analysis showed that compared with metformin users with the lowest dose 
(DDDs <175), the point estimates were lower in the intermediate dose group (HR 0.91, 95% CI 
0.51-1.63) and in the high dose group (HR 0.89, 95% CI 0.49-1.61), but these were not statistically 
significant (online supplementary Table 4). 
 
Sensitivity analyses 
In analyses excluding participants with other cancer before ESCC (sensitivity analysis 1) or 
participants with less than one year of follow up (sensitivity analysis 2), the results remained 
unchanged (Table 2).  
 
Influence of unmeasured confounding 
Online supplementary Figure 2 shows the influence of unmeasured confounders on the observed 
relative risk for the association between metformin use and ESCC risk. Under the assumption that 
odds ratios of metformin use for non-smoking and non-alcohol overconsumption were 0.22 and 
0.32, respectively, and the relative risk of ESCC for non-smoking and non-alcohol 
overconsumption were 0.76 and 1.05, respectively, potential unmeasured confounding from 
smoking and alcohol overconsumption should not alter the observed relative risk to null. Moreover, 
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in order for the upper bound of the confidence interval of 0.85 to cross 1.0, if, e.g., the odds ratio 
between metformin and confounder is 2.13, then that confounder has to decrease the relative risk 
of ESCC to as low as 0.34 or lower.  
 
Adherence to metformin therapy 
The percentage of participants who were adherent to metformin therapy was approximately 80% 
each year during the follow-up years, indicating relatively high and stable drug adherence and 
validity of the study (online supplementary Figure 3). 
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CONCLUSIONS    
This study indicates a decreased risk of ESCC among metformin users compared to non-users of 
metformin. The inverse association remained after considering the influence of confounding 
factors, competing risk from death, detection bias, residual or unmeasured confounding, and 
adherence to metformin therapy.  
 
This study is the first to examine metformin use in relation to the risk of ESCC. Strengths include 
the large sample size, population-based cohort design, use of high-quality data, and complete 
follow-up. Selection bias should have been negligible in this study because of the Swedish national 
registries with excellent completeness and validity. Exposure information was collected 
prospectively and continuously, which eliminated concerns that may arise from retrospective data 
collection. The matched cohort study design counteracted potential time bias, which is common in 
other types of observational studies. This study also has limitations. The observational design 
cannot rule out unmeasured confounding, e.g., social-economic status, family history of ESCC, or 
concurrent head and neck cancer, as well as dietary and other lifestyle factors. However, some of 
these factors, e.g., family history of ESCC or concurrent head and neck cancer, are not likely to be 
strongly associated with the exposure and would therefore not confound the associations found in 
the present study. Confounding was taken into account by matching for age, sex and calendar 
period and adjusting for several potential confounding factors. Moreover, a rule-out approach 
assessing the influence of unmeasured confounding showed that it was unlikely to account for the 
entire observed reduction in HR of ESCC. Misclassification of medication probably exists, 
because it was not possible to verify that the participants actually used the medication after 
purchase. However, the personal metformin prescription was strictly followed by doctors in the 
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country and the metformin users has to purchase the medicine with their identification card, which 
should strongly increase the probability that they actually used it. Finally, although the study was 
large, some of the sub-group analyses had limited statistical power to verify weak associations. 
 
Without specifying the histological subtypes, a limited number of studies have reported conflicting 
results regarding the association between metformin use and the risk of esophageal cancer (13-16, 
23). A case-control study from Taiwan reported an increased risk (odds ratio 2.84, 95% CI 0.99-
8.18) (24), while decreased risks were instead found in cohort studies from Taiwan (HR 0.49, 95% 
CI 0.35-0.68) (13), and the Netherlands (HR 0.90, 95% CI 0.82-0.97) (14). Other studies reported 
no association between metformin use and esophageal cancer risk (15, 16, 23). The major 
differences in the findings of the available studies could be explained by differences in the 
distribution of squamous cell carcinoma and adenocarcinoma (and other less common histological 
types of esophageal cancer), study design, study population, data collection, adjustment for 
confounders, exposure measurement, comparison groups, and follow-up. A major limitation 
shared by all previous studies was that squamous cell carcinoma and adenocarcinoma were 
combined, although these two have distinct aetiology (6). Importantly, obesity is a strong risk 
factor for esophageal adenocarcinoma and is also strongly associated with diabetes (6, 25). Failure 
to control for the confounding from obesity in these studies could have yielded biased results (26).  
This problem was avoided in the present study because obesity is not a risk factor for ESCC. 
Similarly, diabetes increases the risk of some cancer types, but not ESCC (7, 27).  
 
The decreased risk of ESCC among metformin users in this study remained after a series of 
sensitivity analyses, indicating the robustness of the finding. However, no clear dose-response 
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association was found. This might have been due to the limited power in each group or that only a 
low dose was required to achieve a protective effect. Duration of metformin use and risk of ESCC 
was not analyzed in this cohort study because of concerns for time-related bias and reverse 
causality. The decrease in risk of ESCC was seemingly more pronounced among new metformin 
users, who started with a low dose, which may indicate a benefit of low-dose medication. Another 
explanation is that single-use of metformin is more common among new metformin users, while 
longer-term users more often also use other anti-diabetes medications, e.g., sulfonylurea or insulin, 
which can increase the risk of ESCC (24). The stratified analyses by age showed decreased point 
estimates of HRs in all age groups, but the association was statistically significant only in the age 
group 60-69 years. The lack of statistically significant association in the younger age group (≤59 
years) might be explained by the low incidence of ESCC in younger age groups in combination 
with the relatively short follow-up (on average six years). In the older age group (≥70 years) higher 
competing risk from mortality in diabetes patients could explain the weaker association. Yet, 
because of the lower power in the stratified analyses, the possible differences in findings regarding 
new metformin users and the age groups should be interpreted with caution.   
 
Biological mechanisms that may explain how metformin may counteract cancer development have 
been widely investigated. Metformin modulates hyperinsulinemia by interruption of insulin 
binding to the insulin receptor or the insulin-like growth factor-1 receptor. This leads to 
deactivation of the phosphoinositide 3-kinase pathway or mitogen-activated protein-kinase, 
reduction of protein synthesis, and cell proliferation (28). Metformin can also deplete energy in 
cells and activate the 5’ adenosine monophosphate-activated protein kinase (AMPK) pathway, the 
cellular energy regulator center, and influence protein synthesis, lipogenesis, angiogenesis, cell 
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cycle arrest, interruption of cancer stem cell differentiation, and promotion of anti-inflammation 
(8). Activation of AMPK by metformin is a necessary mediator of the tumor suppressor liver 
kinase B1 (LKB1), especially in patients with metabolic syndrome, e.g., diabetes (29). The 
anticancer properties of metformin may also be due to the promotion of autophagy and activation 
of the immune system (8). However, mechanisms specific for ESCC remain to be investigated.  
 
The reduced risk of ESCC among metformin users identified in this study remains to be validated 
in independent populations. If the strongly decreased risk found in this study is supported by 
further research, it may lay the foundation for randomized clinical trials in high-risk populations 
of ESCC, e.g., in parts of France, China, and Japan (30).   
 
In conclusion, this nationwide and population-based cohort study in Sweden indicates that 
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Number (%)  
Age, mean years (SD) 59.0 (±13.7) 59.0 (±13.7) 59.0 (±13.7) 
Sex     
 Men 2,632,960 (58.2) 239,360 (58.2) 2,393,600 (58.2) 
 Women  1,894,673 (41.8) 172,243 (41.8) 1,722,430 (41.8) 
Residence in Sweden    
 Eastern/Southern 3,604,966 (79.6) 320,963 (78.0) 3,284,003 (79.8) 
 Northern  913,051 (20.2) 90,074 (21.9) 822,977 (20.0) 
 Unknown 9,616 (0.2) 566 (0.1) 9,050 (0.2) 
Smokinga   115,347 (2.5) 11,794 (2.9) 103,553 (2.5) 
Alcohol overconsumptiona 112,486 (2.5) 10,427 (2.5) 102,059 (2.5) 
Use of NSAIDs or aspirin 1,666,716 (36.8) 200,182 (48.6) 1,466,534 (35.6) 
Use of statins  1,041,094 (23.0) 212,815 (51.7) 828,279 (20.1) 
Duration of follow-up, mean years (SD) 5.8 (±3.4) 6.0 (±3.4) 5.8 (±3.5) 
ESCC cases  1,352 (0.03) 86 (0.02) 1,266 (0.03) 
ESCC incidence per 100,000 person-years 
(95% CI) 5.1 (4.8-5.4) 3.5 (2.8-4.3) 5.3 (5.0-5.6) 
Death during follow-up 598,899 (13.2) 71,409 (17.4) 527,490 (12.8) 
New metformin usersb NA 264,641 (64.3) NA 
a Assessed within the ten years before study entry 
b New metformin user if without any metformin use between 2005-07-01 and 2006-06-30 
Abbreviations: ESCC=esophageal squamous cell carcinoma, NSAIDs= non-steroidal anti-inflammatory drugs, NA=not 




Table 2. Risk of esophageal squamous cell carcinoma (ESCC) in metformin users 
compared with matched non-users of metformin in Sweden in 2005-2015  
Analysis ESCC (number) 
Hazard ratio (95% confidence interval) 
Model 1     Model 2 Model 3 
Metformin use  1,348 0.66 (0.53-0.82) 0.67 (0.54-0.84) 0.68 (0.54-0.85) 
New metformin use 627 0.46 (0.32-0.67) 0.46 (0.31-0.67) 0.44 (0.28-0.64) 
Sensitivity analysis 1a 1,210 0.68 (0.54-0.85) 0.69 (0.55-0.87) 0.70 (0.56-0.88) 
Sensitivity analysis 2b 1,142 0.66 (0.52-0.84) 0.67 (0.53-0.85) 0.68 (0.53-0.86) 
Model 1: crude analysis     
Model 2: adjusted by age, sex, calendar year, residence, smoking, and alcohol overconsumption  
Model 3: model 2 further adjusted by non-steroidal anti-inflammatory drugs/aspirin and statin use 
a Censored those who developed any other cancers (except for non-melanoma skin cancer) before ESCC during 
follow-up 
b Excluded those with less than one-year follow-up, regardless of exposure status and reasons for the end of 
follow-up 
Note: All results met the proportionality assumption of the hazard  
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Table 3. Risk of esophageal squamous cell carcinoma 
(ESCC) in metformin users compared with matched non-
users of metformin in Sweden in 2005-2015, stratified by 




Hazard ratio  
(95% confidence interval) a 
Total  1,348 0.68 (0.54-0.85) 
Sex    
 Men 972 0.70 (0.54-0.90) 
 Women 376 0.62 (0.39-0.97) 
Age, years   
 ≤59 279 0.90 (0.56-1.45) 
 60-69 595 0.45 (0.31-0.66) 
 ≥70 474 0.92 (0.66-1.29) 
Calendar period  
 2005-2009 1,094 0.67 (0.52-0.86) 
  2010-2015 254 0.69 (0.41-1.16) 
a Adjusted for age, sex, calendar year, residence, smoking, and alcohol 
overconsumption, non-steroidal anti-inflammatory drugs/aspirin and 
statin use, except for the evaluation variable. 




Figure 1: Cumulative incidence of patients developing esophageal squamous cell carcinoma 




LEGENDS OF SUPPLEMENTARY MATERIALS  
Supplementary Table 1: International Classification of Diseases (ICD) codes for outcomes and 
covariates 
Supplementary Table 2: Anatomical Therapeutic Chemical (ATC) codes for exposure and 
covariates 
Supplementary Table 3: Baseline characteristics of sub-cohort of new metformin users 
Supplementary Table 4: Risk of esophageal squamous cell carcinoma (ESCC) in metformin 
users with dosage level during the first year (expressed as defined daily dose, DDD) in Sweden 
in 2005-2015. 
 
Supplementary Figure 1: Flowchart of participants’ enrolment 
Supplementary Figure 2: Influence of unmeasured confounders on the observed relative risk of 
metformin use and esophageal squamous cell carcinoma  
X-axis: relative risk (RRCD) of unmeasured confounder and esophageal squamous cell carcinoma 
(ESCC, outcome); Y-axis: odds ratio (OREC) of metformin use (exposure) and unmeasured 
confounder. The solid line shows the association between RRCD and OREC when the apparent 
(observed) relative risk (ARR) between metformin use (exposure) and ESCC (outcome) is 0·68 and 
when the true relative risk is 1. The dashed line shows the association between RRCD and OREC 
when the ARR between metformin use and ESCC is 0·85 and when the true relative risk is 1. The 
analysis was under the assumption of a prevalence of the confounder of 80% and a prevalence of 
metformin use of 9%. Any combination of RRCD and OREC that lies in the area to the lower right 
of each line indicates the unmeasured confounders that would not move the ARR to the null. 
Supplementary Figure 3: Percent of adherent to metformin therapy among metformin users 
during follow-up 
 
